Phase 4 bosutinib study in previously treated Philadelphia chromosome-positive chronic myeloid leukemia

Phase 4, open-label, single-arm trial of bosutinib in chronic myelogenous leukemia (CML), sponsored by Pfizer. Primary endpoints: 1-year cumulative major cytogenetic response in chronic phase patients with 1 or 2 prior TKI lines, 1-year cumulative major cytogenetic response in chronic phase patients with 3 or more prior TKI lines and 1 more. Planned start Jun 2014; status: withdrawn.